1. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. (23rd August 2018) Authors: Kron, A; Alidousty, C; Scheffler, M; Merkelbach-Bruse, S; Seidel, D; Riedel, R; Ihle, M A; Michels, S; Nogova, L; Fassunke, J; Heydt, C; Kron, F; Ueckeroth, F; Serke, M; Krüger, S; Grohe, C; Koschel, D; Benedikter, J; Kaminsky, B; Schaaf, B Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2068 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 55PEfficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455). (17th December 2018) Authors: Grohe, C; Gleiber, W; Haas, S; Mueller-Huesmann, H; Schulze, M; Atz, J; Kaiser, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA61Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Tan, D S; Kim, S-W; Sequist, L V; Ponce Aix, S; Smit, E F; Hida, T; Yang, J C-H; Felip, E; Seto, T; Grohe, C; Wolf, J; Ko, J; Marriere, E; Belli, R; Giovannini, M; Kim, D-W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1504TiPNintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape. (23rd October 2018) Authors: Grohe, C; Zander, I; Lüdtke-Heckenkamp, K; Blau, W; Krüger, S; Franke, C; Mueller-Huesmann, H; Brückl, W M; Basara, N; Ukena, D; Lang, S; Atz, J; Kaiser, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 66P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455). (15th December 2019) Authors: Grohe, C; Gleiber, W; Krüger, S; Mueller-Huesmann, H; Schulze, M; Atz, J; Kaiser, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗